Sensex

Monday, May 28, 2007

$$ DreamGains !! $$ FW: Sharekhan Post-Market Report dated May 28, 2007

 

 

From: The Sharekhan Research Team [mailto:marketwatch@research.sharekhan.com]
Sent: 28 May 2007 17:11
To: The Sharekhan Research Team
Subject: Sharekhan Post-Market Report dated May 28, 2007

 

 

 Sharekhan's daily newsletter

Visit us at www.sharekhan.com

 

May 28, 2007

 

Index Performance

Index

Sensex

Nifty

Open

14,467.85

4,248.35

High

14,527.47

4,295.60

Low

14,368.40

4,242.80

Today's Cls

14,397.89

4,256.55

Prev Cls

14,338.45

4,248.15

Change

59.44

8.40

% Change

0.41

0.20

 

Market Indicators

Top Movers (Group A)

Company

Price 
(Rs)

%
chg

Gainers

Nirma

198.30

20.00

iGate Global

352.20

9.45

Thermax

480.90

9.27

Ingersoll Rand

336.10

7.69

Welspun Gujarat 

172.10

6.79

Losers

SKF India

461.90

-7.25

Suzlon Energy

1,281.90

-7.00

IndusInd Bank

48.10

-2.73

Torrent Pharma

246.30

-2.51

HCL Tech

342.75

-2.18

Market Statistics

-

BSE

NSE

Advances

1,470

606

Declines

1,094

442

Unchanged

97

36

Volume(Nos)

25.25cr

42.75cr

 Market Commentary 

Market gains 59 points

The market closed with gains, but slipped over 129 points from the day's high of 14527.

The strong global markets and prevailing strong bullish sentiment helped the Sensex to open with a huge positive gap of 130 points at 14468. The wide-based National 

 

Stock Exchange's Nifty hit an all-time high of 4296 points within the mid-morning trades. The Asian indices like China's Shanghai Composite Index and South Koria's KOSPI Composite Index also hit news highs, while a rally in metal prices and a stronger dollar helped to gain Japanese export shares. Mirroring the same the Sensex gained 189 points on touching the day's high of 14527. The buoyancy in heavyweights and banking stocks kept the market bias up but the market moved in a narrow range throughout the session. Profit booking in a few front-line stocks towards the close dragged the Sensex to the intra-day low of 14368. The Sensex finally wrapped up the session with the gains of 59 points at 14398. The Nifty closed the session at 4257 by adding nine points. 

The breadth of the market was positive. Of the 2,661 stocks traded on the BSE, 1,470 stocks advanced, 1,094 stocks declined and 97 stocks ended unchanged. Among the sectoral indices the BSE Bankex advanced by 1.29% at 7564 followed by the BSE Auto index (up 1.19% at 4918) and the BSE HC (up 1.26% at 3793). However, the BSE IT index, the BSE Metal index and the BSE Teck index closed in negative territory.

Movers & Shakers

  • Ranbaxy Laboratories gained marginally on acquiring the US rights for 13 dermatology products from Bristol-Myers Squibb Company.
  • Ruchi Infrastructure hit the upper circuit on signing an MoU with Madhya Pradesh government for rural aggregation and infrastructure projects.
  • Venus Remedies slipped despite filling its first PCT application for its research product, "Non-Aqueous, Liquid Parenteral Formulation" in 49 countries.
  • TCS closed in the red despite increasing its stake from 51% to 100% in the joint venture IT services company TCS do Brasil.
  • Accentia Technologies surged on the reports that the company will set up a subsidiary in the UAE to cater to the increasing demand for BPO products of the company.


Select front-line stocks notched up significant gains. HDFC Bank rose 5.23% at Rs1,125, L&T advanced 2.65% at Rs1,785, Gujarat Ambuja Cement climbed 1.93% at Rs116, Maruti Udyog surged 1.87% at Rs825, Cipla scaled up 1.61% at Rs208, Bajaj Auto added 1.49% at Rs2,203, HDFC jumped 1.45% at Rs1,845, ACC moved up by 1.39% at Rs870, Reliance Communications gained 1.28% at Rs510 and ICICI Bank was up 1.01% at Rs922. Among the laggards, HLL slipped by 1.28% at Rs201 and Infosys dropped 1.09% at Rs1965 while Reliance Energy, NTPC, Satyam Computer, Wipro, TCS and Bharti Airtel ended with marginal losses.

Banking stocks were in the limelight. Andhra Bank soared 5.43% at Rs91, Allahabad Bank jumped 4.99% at Rs89, Bank of Baroda scaled up 2.14% at Rs276, Oriental Bank advanced 1.85% at Rs234 and Canara Bank gained 1.63% at Rs262. 

Over 3 crore Reliance Natural Resources shares changed hands on the BSE followed by Reliance Petroleum (79.56 lakh shares), Dish TV (60.16 lakh shares), Binani Cement (57.62 lakh shares) and Nagarjuna Fertilizers (46.09 lakh shares).

Value-wise India Infoline registered a turnover of Rs134 crore on the BSE followed by Unitech (Rs123 crore), Advanta (Rs119 crore), Reliance Natural Resources (Rs109 crore) and Reliance Capital (Rs98 crore).

European Indices at 16:15 IST on 28-05-2007

Index

Level

Change (pts)

Change (%)

FTSE 100

6570.50

5.10

0.08

CAC 40 Index

6055.78

-1.71

-0.03

DAX Index

7739.20

41.82

0.54

Asian Indices at close on 28-05-2007

Index

Level

Change (pts)

Change (%)

Nikkei 225

17587.59

106.38

0.61

Hang Seng

20529.76

9.10

0.04

KOSPI Composite

1657.91

13.35

0.81

Straits Times Index

3513.37

26.74

0.77

Jakarta Composite Index

2076.76

16.32

0.79

“This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.
Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees (“SHAREKHAN and affiliates”) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. 
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN.”

To unsubscribe write to myaccount@sharekhan.com

 

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

New web site?

Drive traffic now.

Get your business

on Yahoo! search.

Yahoo! Groups

Take a Survey

express your ideas

share your opinion

.

__,_._,___

$$ DreamGains !! $$ FW: Aurobindo Pharma: Sharekhan Stock Idea dated May 28, 2007

 

 

From: The Sharekhan Research Team [mailto:marketwatch@research.sharekhan.com]
Sent: 28 May 2007 15:46
To: The Sharekhan Research Team
Subject: Aurobindo Pharma: Sharekhan Stock Idea dated May 28, 2007

 

Stock Idea
[May 28, 2007] Please see the attachment for details

Sharekhan
www.sharekhan.com

Summary of Contents

STOCK IDEA

Aurobindo Pharma            
Cluster: Ugly Duckling
Recommendation: Buy
Price target: Rs914
Current market price: Rs684

Betting big on formulation growth 

Key points 

  • Formulation business grows at 62.2% CAGR: Aurobindo Pharma (Aurobindo) has created a robust product pipeline of 1,172 formulation dossiers for various markets and expects major growth in its speciality generic formulation business. The formulation sales are expected to gallop at a CAGR of 62.2% over FY2006-09.
  • Robust product pipeline: During FY2007, Aurobindo filed 32 ANDAs and 41 DMFs, taking the cumulative DMF filings to 110 and ANDA filings to 82 in the US market. With the recent USFDA approval for products like Bisoprolol, Simvastatin and Zolpidem tartarate, we estimate incremental revenue of Rs100 crore from the US generic business during FY2008.
  • European business to expand at over 50%: Aurobindo expects to deliver over 50% growth in Europe on the back of increased product registrations and synergetic benefits flowing from the recent acquisitions of Milpharm in the UK and Pharmacin in the Netherlands. It is also contemplating a couple of mid-sized acquisitions in Europe.
  • Steady growth in ARV business: With most of the registrations taking place in the recent past, we expect Aurobindo to see steady growth in its ARV formulation revenues. We estimate the ARV formulation business would generate revenues worth $99 million and $128.7 million in FY2008 and FY2009 respectively.
  • Consolidated PAT to grow at 70% CAGR: Going forward, the increasing traction in formulation exports would help the consolidated revenue to grow at a 24.3% CAGR during FY2006-09E(Rs3,143.1 crore in FY2009E). The adjusted net profit would gallop at a CAGR of 70% during FY2006-09 (Rs348.4 crore in FY2009E), translating into earnings of Rs57.1 per share.
  • Buy with price target of Rs914: At the current market price of Rs684, Aurobindo is trading at 14.9x its FY2008E and 12.0x its FY2009E earnings. We initiate coverage on Aurobindo with a Buy recommendation and a one-year price target of Rs914 (an upside of 34% from the current levels). The price target discounts the FY2009E earnings by 16x.

Regards,
The Sharekhan Research Team

myaccount@sharekhan.com

 

 

FREE FirstStep Seminar! Book your seat TODAY!
To buy and sell shares, log on to www.sharekhan.com or call our DialnTrade unit on 1-800 227050/ 30307600.
For account related queries call our Customer Service cell on 1-800-22-7500/ 39707500 or mail us at myaccount@sharekhan.com.

 

Sunday, May 27, 2007

$$ DreamGains !! $$ Planning To Subscribe Few NL (Must Read & IMP)

Hello Members
 
I'm planning to subscribe few NLs again.
 
Please send me your suggestions.
 
Also let me know which NL have you subscribed yourself & can contribute consistently so that I dont re-subscribe them.
 
It would be great if we could share the NLs so that we can subscribe to maximum NLs as I personally cannot afford all.
 
Lets joint hands together and work the things.
 
Regards
 
Rohit

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

New business?

Get new customers.

List your web site

in Yahoo! Search.

Yahoo! Groups

Take a Survey

express your ideas

share your opinion

.

__,_._,___

$$ DreamGains !! $$ The success story of Sun Pharma

The success story of Sun Pharma
Shobhana

May 25, 2007

For a company that started in 1983 with just five people and five
products, it's no mean achievement that Sun Pharma today commands the
largest market capitalisation of Rs 21,271 crore (Rs 212.71 billion)
in the pharma universe.

Thanks to a strategy that focuses on niche segments such as psychiatry
and lifestyle drugs, the company has raced ahead, with its business
growing four-fold between 1999-2000 and now, with revenues of Rs 2,237
crore (Rs 22.37 billion).

The story goes that the reason chairman and managing director Dilip
Shanghvi decided to manufacture medicines for psychiatry, when he set
up his first unit at Vapi in Gujarat, was that the number of
psychiatrists was few and so it would be easier to reach out to them
rather than sell to a whole lot of general physicians, which would
require a large field force.

Whatever the reason, Sun, from the very beginning, has focussed on the
high-margin chronic care therapy products that have made the company
very profitable.

Together with a head for numbers, Shanghvi -- who started life as a
wholesaler of pharmaceutical products in Kolkata where his father ran
a business -- has a knack for turning around companies.

Most of his acquisitions have been of distressed assets. Known to be
extremely conservative, with his feet firmly on the ground,
51-year-old Shanghvi has desisted from overpaying for assets or
getting carried away by bids from peers, preferring instead to bide
his time.

That's possibly why Sun hasn't made any big acquistions since it first
bought into the Detroit-based Caraco Pharma in 1987 and took over,
over a period of time for $50 million. Initially, the Caraco takeover
seemed to be a wrong move -- it was in the red for several years --
and the Sun management perhaps miscalculated the timelines required to
sort out some of the US FDA issues that Caraco faced.

Shanghvi, however, persevered and finally Caraco is making money.
Industry watchers are convinced that Sun's more recent takeovers,
including Valeant and Able Pharma, too will soon turn profitable.

Sun Pharma's buyouts have been well thought out. In almost every
instance the company has managed to diversify into a new area. When it
acquired Tamil Nadu Dadha Pharma it gained entry into the oncology
space; with Milmet Labs it was able to acquire expertise in
ophthalmology, while with Valeant it penetrated the controlled
substances segment.

The story is much the same with its latest acquisition,the
Israel-based Taro, which Sun has bought for an enterprise value of
$454 million. The $300 million generics player, which has a subsidiary
in Canada, is a strong contender in the dermatology segment which
accounts for more than 50 per cent of its revenues.

Taro is strategically a good fit for Sun because, as the soft-spoken
and down to earth Shangvi says, it will help Sun tap into the former's
customer base in Canada, Europe and US and sell Caraco's existing
portfolio of products to them. Taro may not be in great shape
financially -- it made a loss in 2006 -- but then Shanghvi should not
have too much trouble turning it around.

When Sun Pharma first started selling its products on a national
scale, way back in 1987, it ranked a low 108 on the ORG list. Today,
with a domestic market share of 3.2 per cent, it is ranked number six.
The numbers tell the story: whether it's building a profitable
business or creating wealth for his shareholders, Shanghvi's done a
great job.

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Ads on Yahoo!

Learn more now.

Reach customers

searching for you.

Yahoo! Groups

Take a Survey

express your ideas

share your opinion

.

__,_._,___

Saturday, May 26, 2007

$$ DreamGains !! $$ FW: Daily Newsletter !



-----Original Message-----
From: Capital Market [mailto:cmnews@news.capitalmarket.com]
Sent: 26 May 2007 19:41
To: justrohit@gmail.com
Subject: Daily Newsletter !

************************************************************
capitalmarket.com Daily Newsletter [Saturday, May 26, 2007]
************************************************************

Capita Telefolio
The market cannot be timed. But you can tame the market and come out trumps
if you have the right information at the right time. To make informed
decisions, you need to have all the information at your disposal at the
click of a button. Invest in Telefolio and Telefolio Plus to reap the power
of knowledge. Do so before 31 May 2007 and avail of a 10% discount!
Click on http://www.telefolio.com

STOCK INDICES
----------------------------------
18-May-07 25-May-07 ±
----------------------------------
BSE 14303.41 14338.45 35.04
NSE 4214.50 4248.15 33.65
----------------------------------

Stocks - Weekly Review
Market ends with small gains
The market ended the week with small gains, on account of mixed trend in
index pivotals.
http://www.capitalmarket.com/ns.asp?SH=marketnews&St=cmedit%2fstory1-7.asp
%3fsno%3D165360

ApnaMoney - Online family portfolio module Stocks, Funds, FDs, Insurance,
RBI Bonds, Bullion, Real Estate Monitor the online multi-asset portfolio of
all your family members from a single login
http://www.apnamoney.com?website=Newsletter

Market Beat

FII inflows Rs 319.50 crore on 24 May 2007
http://www.capitalmarket.com/ns.asp?SH=marketnews&St=cmedit%2fList4-15.asp

Mutual Funds

Mutual funds turn sellers
Extension of NFO of HSBC MF
http://www.capitalmarket.com/ns.asp?SH=marketnews&St=cmedit%2fList10-22.as
p

Other Markets

Call money trades firm
http://www.capitalmarket.com/ns.asp?SH=marketnews&St=cmedit%2fList13-48.as
p

Politics

7 killed and 18 injured in Assam blasts
http://www.capitalmarket.com/ns.asp?SH=marketnews&St=cmedit%2fList17-0.asp

The following are paid sections.
To susbscribe visit http://www.capitalmarketplus.com/registration.asp

Corporate Results
Solitaire Machine Tools net profit rises 23.17% in the year ended March
2007
Amrapali Industries reports net profit of Rs 1.47 crore in the year ended
March 2007 Action Financial Services (I) reports net loss of Rs 0.03 crore
in the March 2007 quarter Fortune Financial Services (India) net profit rise
29.05% in the March
2007 quarter
Bafna Spinning Mills & Exports reports net profit of Rs 0.16 crore in the
March 2007 quarter Amradeep Industries net profit rises 50.00% in the March
2007 quarter Amraworld Agrico net profit dips 42.11% in the March 2007
quarter Amrapali Developers (India) net profit dips 25.00% in the March 2007
quarter Brindaban Holdings and Trading net profit dips 50.00% in the March
2007 quarter KG Petrochem reports net profit of Rs 1.26 crore in the March
2007 quarter Usha International net profit rises 7.18% in the March 2007
quarter SMC Global Securities net profit rises 90.24% in the March 2007
quarter State Bank of Indore net profit dips 4.86% in the March 2007 quarter
Sam Global Securities net profit rises 388.32% in the March 2007 quarter My
Fair Lady reports net loss of Rs 0.23 crore in the March 2007 quarter JBM
Auto net profit rises 26.85% in the March 2007 quarter Kadambini Commercial
net profit remains constant at Rs 0.01 crore in the year ended March 2007
Victor Commercial Company net profit dips 33.33% in the March 2007 quarter
Deepa Trade & Commerce net profit remains constant at Rs 0.01 crore in the
March 2007 quarter Pioneer Protec reports net profit of Rs 0.06 crore in the
March 2007 quarter J S M Investments reports net profit of Rs 0.04 crore in
the March 2007 quarter

Corporate News
Repro India recommends dividend
Fortune Financial Services India recommends final dividend Satra Properties
appoints independent directors Reliance Chemotex Industries recommends
dividend Sheetal Bio Agro Tech consolidates face value of equity shares
Banswara Syntex recommends dividend JBM Auto recommends dividend

Subscribe to CAPITAL MARKET magazine for indepth coverage of the stock
markets. Click on http://financeshop.capitalmarket.com?website=Newsletter

Careers@CAPITAL MARKET : Business correspondent / Sector Analyst CAPITAL
MARKET, India`s leading fortnightly investment magazine, which also
publishes electronic database Capitaline, has exciting career opportunities.
For details click here
http://www.capitalmarket.com/careers/BusinessCorrespondents.asp

You are subscribed to the Capital Market newsletter under e-mail ID
'justrohit@gmail.com'
To unsubscribe, please click here.
http://www.capitalmarket.com/newsletter/unsubscribe.asp?Email=justrohit@gm
ail.com

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Need traffic?

Drive customers

With search ads

on Yahoo!

Yahoo! Groups

Take a Survey

express your ideas

share your opinion

.

__,_._,___